The inhibition of VEGF axis through the treatment with bevacizumab shows paracrine effects on endothelial cells and other cancer cells thus reducing tumor growth in mice injected with CD133+ GSCs in terms of weight, vascularity, and hemorrhage [78]. The gene discussed is VEGFA; the disease is neoplasm.